Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| PBTC-056 | PBTC | A Phase I study of the ADAM-10 inhibitor, INCB7839 in children with recurrent/progressive high-grade gliomas to target microenvironmental neuroligin-3 | Pediatric CIRB | Available to Open | |
| PBTC-058 | PBTC | Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma | Pediatric CIRB | Available to Open | |
| PBTC-059 | PBTC | Phase 1 Trial of Autologous HER2-specific CAR T cells in Pediatric Patients with Refractory or Recurrent Ependymoma | Pediatric CIRB | Available to Open | |
| PBTC-060 | PBTC | A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | Pediatric CIRB | Available to Open | |
| PBTC-061 | PBTC | Phase 2 Trial of G207 + 5 Gy Radiation for Children with High-Grade Gliomas | Pediatric CIRB | Available to Open | |
| PBTC-N14 | PBTC | CSF Cell-free Tumor DNA (CSF cfDNA) Liquid Biopsies for Pediatric, Adolescent, and Young Adult Patients with Primary Brain Tumors | Pediatric CIRB | Available to Open | |
| PED-CITN-01 | Pediatric CITN | 3CI Study: Childhood Cancer Combination Immunotherapy. Phase 1b and Expansion Study of Nivolumab Combination Immunotherapy in Children, Adolescent and Young Adult (CAYA) Patients with Relapsed/Refractory Hypermutant Cancers | Pediatric CIRB | Completed | |
| PED-CITN-02 | Pediatric CITN | GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Sarcoma and Neuroblastoma to Increase Systemic Tumor Exposure | Pediatric CIRB | Available to Open | |
| PED-CITN-03 | Pediatric CITN | Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined with Dinutuximab in Children and Young Adults with Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma | Pediatric CIRB | Available to Open | |
| PEPN1812 | PEP-CTN | A Phase 1 Trial of the CD123 X CD3 DART® Molecule Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia | Pediatric CIRB | Available to Open |